Answering the Call
Our world-class team of biotechnology and biopharmaceutical experts aim to fulfill an unmet need in the field of anti-infectives, currently underserved by traditional biotech and pharmaceutical companies. It is our mission to bring hope to patients and families of loved ones suffering from serious infections and rare orphan diseases.
Late stage pipeline addressing major unmet needs
Includes Phase 2 ready program in NTM and additional partnership directed programs
An Oral Antibiotic Designed to Treat Nontuberculous Mycobacterial Pulmonary Disease, a Rare Orphan Disease.
SPR720 has potential to be the first approved novel oral agent for Nontuberculous mycobacteria (NTM), addressing a significant unmet need to arrest infection and prevent the lung damage that infection causes.
There is a desperate need to find a new suite of drugs that can arrest NTM infection and prevent the lung damage that infection causes.
SPR206 is a direct acting intravenous (IV)-administered next-generation polymyxin analogue developed from our potentiator platform that is in clinical development as an innovative potential option to treat MDR Gram-negative bacterial infections within the hospital.
Tebipenem HBr is a novel antibiotic with the potential to be the first oral carbapenem for use in adults to treat complicated urinary tract infection and acute pyelonephritis.
Spero Therapeutics is pursuing collaborations with partners for expertise and funding support.
Stock information, SEC filings, corporate governance, IR resources and more.
Collaborative. Exciting. Challenging. Stimulating. Committed. Spero Therapeutics was founded in 2013.